Allianz Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-20,300
| Closed | -$67.6K | – | 2155 |
|
|
2025
Q1 | $67.6K | Buy |
+20,300
| New | +$105K | ﹤0.01% | 2186 |
|
|
2024
Q2 | – | Sell |
-20,800
| Closed | -$308K | – | 2190 |
|
|
2024
Q1 | $308K | Buy |
+20,800
| New | +$242K | ﹤0.01% | 1744 |
|
|
2023
Q4 | – | Sell |
-18,500
| Closed | -$84.2K | – | 2185 |
|
|
2023
Q3 | $84.2K | Hold |
18,500
| – | – | ﹤0.01% | 2149 |
|
|
2023
Q2 | $130K | Sell |
18,500
-12,300
| -40% | -$88K | ﹤0.01% | 1908 |
|
|
2023
Q1 | $188K | Buy |
+30,800
| New | +$213K | ﹤0.01% | 2046 |
|
|
2022
Q4 | – | Sell |
-31,700
| Closed | -$304K | – | 2007 |
|
|
2022
Q3 | $304K | Sell |
31,700
-48,180
| -60% | -$556K | ﹤0.01% | 1597 |
|
|
2022
Q2 | $882K | Buy |
79,880
+26,380
| +49% | +$346K | ﹤0.01% | 1715 |
|
|
2022
Q1 | $891K | Hold |
53,500
| – | – | ﹤0.01% | 1899 |
|
|
2021
Q4 | $1.02M | Buy |
53,500
+26,995
| +102% | +$594K | ﹤0.01% | 1899 |
|
|
2021
Q3 | $654K | Sell |
26,505
-28,920
| -52% | -$681K | ﹤0.01% | 2115 |
|
|
2021
Q2 | $1.44M | Sell |
55,425
-10,391
| -16% | -$270K | ﹤0.01% | 1599 |
|
|
2021
Q1 | $2.08M | Sell |
65,816
-74,464
| -53% | -$3.09M | ﹤0.01% | 1390 |
|
|
2020
Q4 | $6.51M | Sell |
140,280
-1,808
| -1% | -$71.8K | 0.01% | 971 |
|
|
2020
Q3 | $4.68M | Sell |
142,088
-67,463
| -32% | -$2.07M | 0.01% | 998 |
|
|
2020
Q2 | $5.75M | Buy |
209,551
+42,343
| +25% | +$1.39M | 0.01% | 1144 |
|
|
2020
Q1 | $5M | Sell |
167,208
-42,371
| -20% | -$1.12M | 0.01% | 1161 |
|
|
2019
Q4 | $5.8M | Buy |
209,579
+78,247
| +60% | +$1.78M | 0.01% | 1415 |
|
|
2019
Q3 | $2.38M | Sell |
131,332
-162,071
| -55% | -$3.58M | ﹤0.01% | 1760 |
|
|
2019
Q2 | $7.19M | Sell |
293,403
-294,192
| -50% | -$4.43M | 0.01% | 1339 |
|
|
2019
Q1 | $5.59M | Buy |
587,595
+101,671
| +21% | +$988K | 0.01% | 1401 |
|
|
2018
Q4 | $4.3M | Sell |
485,924
-459,517
| -49% | -$4.43M | ﹤0.01% | 1474 |
|
|
2018
Q3 | $10.6M | Buy |
945,441
+237,162
| +33% | +$3.37M | 0.01% | 1234 |
|
|
2018
Q2 | $9.07M | Buy |
708,279
+530,153
| +298% | +$7.75M | 0.01% | 1286 |
|
|
2018
Q1 | $3.01M | Sell |
178,126
-12,849
| -7% | -$195K | ﹤0.01% | 1744 |
|
|
2017
Q4 | $1.53M | Sell |
190,975
-3,447
| -2% | -$27.7K | ﹤0.01% | 2105 |
|
|
2017
Q3 | $1.51M | Sell |
194,422
-414
| -0.2% | -$2.62K | ﹤0.01% | 2105 |
|
|
2017
Q2 | $1.43M | Buy |
194,836
+4,916
| +3% | +$31.3K | ﹤0.01% | 2100 |
|
|
2017
Q1 | $1.42M | Sell |
189,920
-2,748
| -1% | -$20.1K | ﹤0.01% | 2121 |
|
|
2016
Q4 | $1.34M | Sell |
192,668
-27,707
| -13% | -$191K | ﹤0.01% | 2122 |
|
|
2016
Q3 | $1.81M | Buy |
+220,375
| New | +$1.86M | ﹤0.01% | 2025 |
|
Other funds holding IOVA
MFM
LFCM
ICM
Allianz Asset Management's IOVA Position: Q2 2025 in Review
Allianz Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 20,300 shares — an estimated $67.6K sold.
Allianz Asset Management first reported a position in IOVA in Q3 2016 and held it in 30 quarters. The position peaked at $10.6M in Q3 2018. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.
- Allianz Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
- Allianz Asset Management sold 20,300 Iovance Biotherapeutics shares in Q2 2025, an estimated $67.6K.
- Allianz Asset Management first reported a position in Iovance Biotherapeutics in Q3 2016 and held it in 30 quarters.
- Allianz Asset Management's Iovance Biotherapeutics position peaked at $10.6M in Q3 2018.
- 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.
Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.